Repatha Cost in Delaware 2026: Prices, Insurance, Medicaid, and Compounded Options

Evolocumab is a PCSK9-inhibitor monoclonal antibody sold under the brand name Repatha. It is FDA-approved as an injectable, given either as 140 mg every two weeks or 420 mg once monthly, for patients with established atherosclerotic cardiovascular disease (ASCVD) or certain forms of familial hypercholesterolemia who need additional LDL-lowering beyond statins. It is not the same molecule as inclisiran (Leqvio), a different LDL-lowering injectable with a different dosing schedule and mechanism, and confusing the two can lead to wrong cost or coverage assumptions.

The direct answer: what a Delaware patient actually pays for Repatha depends almost entirely on which payment pathway they qualify for, not on the drug's list price. Commercially insured patients who qualify for the Amgen manufacturer copay card can often pay close to nothing per month; Medicare and Medicaid beneficiaries cannot use that card by federal rule and instead depend on their plan's formulary tier and, for Medicaid, on prior authorization approval; cash-pay patients face the full list price unless they use a legally compounded version from a 503A pharmacy. Because list price, card terms, and plan formularies change over time, this page separates what is stable (FDA approval status, the drug class, the compounding framework) from what must be re-verified close to the date of a fill (exact list price, savings card caps, and Delaware Medicaid or insurer-specific rules).

What actually drives your cost

Repatha's manufacturer list price (the wholesale acquisition cost before rebates) has publicly been reported in the range of several hundred dollars per month in recent years. We are not stating an exact current figure here because list prices change and the sourcing available for this draft does not include a verified, dated 2026 figure. Before assuming a number, confirm the current list price directly with Amgen, a Delaware pharmacy, or a benefits verification tool.

What matters more than the list price for most patients is which of these four pathways applies to them:

1. Commercial insurance plus the Amgen copay card. Most commercial plans place Repatha on a higher formulary tier (commonly tier 3 or 4) and require prior authorization. Patients who clear that prior authorization and then enroll in Amgen's Repatha SupportPlus copay card can typically bring their out-of-pocket cost down substantially, subject to an annual dollar cap that Amgen sets and periodically changes. Enroll before the first fill, since retroactive application is generally not available. Confirm the current cap and terms directly at Amgen's program page, since federal anti-kickback rules also mean this card cannot be used by Medicare or Medicaid beneficiaries.
2. Delaware Medicaid with prior authorization. Coverage exists but is not automatic.
3. Medicare Part D or Medicare Advantage. Coverage varies by plan and formulary tier; the redesigned Part D benefit caps a beneficiary's annual out-of-pocket drug spending, which changes the math for a high-cost biologic like Repatha (see below).
4. Cash pay, including 503A compounded evolocumab. For patients who do not qualify for the above, a state-licensed 503A compounding pharmacy may legally prepare an individualized evolocumab preparation under a valid prescription, generally at a lower cash price than the branded product, though without the same FDA manufacturing and labeling assurances.

Verification checklist: what is stable versus what you must re-check

Use this table as a working checklist rather than a source of numbers: anything in the "date-sensitive" rows should be confirmed at the time a patient is actually filling a prescription, not assumed from an older article.

Delaware Medicaid coverage: what is established and what needs confirmation

Delaware Medicaid can cover evolocumab, but prior authorization is required, and PA criteria for PCSK9 inhibitors generally track the clinical logic in national cholesterol guidelines: documented heterozygous familial hypercholesterolemia or established ASCVD, plus evidence that maximally tolerated statin therapy (with or without ezetimibe) has not brought LDL-C to goal, or documented statin intolerance. This describes the general shape of PA criteria used across many state Medicaid programs, not a verbatim quotation of Delaware's current policy document, and a prescriber submitting a PA should pull Delaware Medicaid's current pharmacy PA form rather than relying on a description in this article. Renewal intervals, the precise LDL-C threshold used, and appeal procedures are the kind of details that change and should be confirmed directly with Delaware Medicaid or the prescribing clinic's PA staff.

Commercial insurance: formulary tier and step therapy

Commercial insurers commonly require prior authorization for PCSK9 inhibitors and may require documentation that a patient has tried a statin, and often ezetimibe, first. This step-therapy pattern is standard across the PCSK9-inhibitor class industry-wide and is consistent with cholesterol-management guideline sequencing (statin, then ezetimibe, then a PCSK9 inhibitor for patients who remain above goal). The specific tier a given Delaware insurer assigns, and the exact PA documentation it requires, differ by plan and should be confirmed with that plan's current formulary rather than assumed.

Patients who believe a prior authorization denial was made in error have a right, under Delaware insurance law, to pursue an internal appeal and then an external independent review through the Delaware Department of Insurance. The general existence of this external review right for insurance denials is well established; the exact procedural steps and timelines should be confirmed on the Delaware Department of Insurance's current consumer resources.

Medicare Part D: the $2,000 cap changes the calculation

Starting in 2025, the redesigned Medicare Part D benefit created an annual cap on out-of-pocket spending for covered Part D drugs, after which the beneficiary owes nothing more for covered drugs for the rest of that plan year. This is an established, dated federal policy change under the Inflation Reduction Act, not a manufacturer program, and it materially changes the annual cost exposure for beneficiaries on an expensive biologic like Repatha compared with the pre-2025 benefit design. The exact cap amount is set annually and may be indexed going forward, so beneficiaries should check the current-year figure on Medicare.gov rather than relying on an older number. Medicare Advantage plans may place Repatha on a different tier than standalone Part D plans, and Amgen's commercial copay card cannot be used by Medicare beneficiaries under federal anti-kickback rules; a separate Amgen patient assistance track for free drug, based on income, exists for those who qualify, and its exact income threshold changes and should be confirmed directly with Amgen.

Compounded evolocumab: legal framework and open questions

Under federal law, a 503A pharmacy may compound a patient-specific preparation of a drug, including a biologic like evolocumab, under a valid prescription from a licensed prescriber, and this is legally distinct from 503B outsourcing facilities that manufacture in bulk. This 503A/503B distinction is a stable part of the federal compounding framework. What is not established from the material available for this article is a specific, current statement that Repatha is (or is not) on any FDA list restricting compounding of it, and that status can change; a prescriber or pharmacy considering this route should check the FDA's current compounding-related lists directly rather than relying on a stated absence.

Compounded evolocumab is not FDA-approved. It does not go through the same manufacturing, batch-testing, and labeling process as the branded product, even when prepared by a fully licensed and USP <797>-compliant sterile compounding pharmacy. Patients considering this route should ask the pharmacy for its current USP <797> accreditation status, its active pharmaceutical ingredient sourcing, and lot-release testing documentation, and should independently verify the pharmacy's Delaware license through the state's Division of Professional Regulation license lookup before sending a prescription there. This is a reasonable cost-reduction option for some cash-pay patients, but it carries a different risk and quality-assurance profile than the FDA-approved product, and that tradeoff should be discussed explicitly with the prescribing clinician.

The clinical case for treatment, briefly

Evaluating evolocumab's cost requires considering the clinical benefits it delivers. A major cardiovascular outcomes trial enrolled patients with established disease and found that evolocumab produced significant additional LDL-C reduction beyond statin monotherapy, along with fewer major cardiovascular events during approximately two years of treatment. Specific efficacy percentages and hazard ratios are omitted from this overview because available references could not be confirmed against the original trial publication, and citing incorrect figures would be more problematic than providing a summary. Clinicians counseling patients about evolocumab should refer directly to the FDA-approved labeling and primary trial results rather than using second-hand summaries of the data.

National cholesterol management guidelines (AHA/ACC) support adding a PCSK9 inhibitor for very-high-risk ASCVD patients whose LDL-C remains above a guideline-specified threshold despite maximally tolerated statin therapy plus ezetimibe. The exact threshold and wording should be confirmed against the current published guideline rather than a paraphrase, since guideline documents are periodically updated.

Monitoring after starting therapy

A follow-up fasting lipid panel four to eight weeks after starting evolocumab is standard practice to confirm response. If LDL-C has not dropped meaningfully, the first steps are usually to check injection technique and adherence before concluding the drug is not working. Evolocumab does not require routine liver-function monitoring the way statins sometimes prompt, because its mechanism does not involve hepatic enzyme metabolism in the same way; a clinician should still individualize monitoring. Injection-site reactions and upper respiratory symptoms are the most commonly reported side effects in trial data; a clinically significant new symptom, chest pain, or a suspected allergic reaction warrants urgent evaluation rather than waiting for a routine follow-up.

Telehealth prescribing in Delaware

Evolocumab is not a controlled substance, so federal controlled-substance telehealth restrictions (which primarily affect stimulants, opioids, and similar drugs) do not apply to it. Delaware's telehealth statute generally requires an established patient-provider relationship and adherence to the standard of care, but does not require an in-person exam specifically for non-controlled medications. A telehealth prescriber still needs to review the patient's lipid history and confirm the qualifying diagnosis before prescribing, and insurance prior authorization requirements apply the same way regardless of whether the prescription originated by telehealth or in person.

Evidence boundaries

Established: Evolocumab is FDA-approved for ASCVD and familial hypercholesterolemia indications; it substantially lowers LDL-C; PCSK9 inhibitors as a class have shown cardiovascular benefit in trial populations with established disease; 503A pharmacies may legally compound patient-specific preparations under a valid prescription; Medicare Part D's out-of-pocket cap structure changed materially starting in 2025.

Plausible but requiring current verification: the exact 2026 list price, the exact Amgen copay card cap and free-drug income threshold, Delaware Medicaid's precise current PA criteria and renewal cadence, and each commercial insurer's current formulary tier for Repatha in Delaware.

Not established from the material available here: any specific cost-effectiveness (cost-per-QALY) figure for evolocumab at a stated price point, and any claim about Repatha's current compounding-restriction status beyond the general 503A framework. Both should be checked against a current, named primary source before being repeated as fact.